GlassScriptPhysician profile
Werner K Brammer
NPI 1710921648
$3,321.14
in general payments reported to CMS, 2019-2025
31 companies · $613 in 2025
The $613 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $77.13 · 2020: $202 · 2021: $573 · 2022: $645 · 2023: $743 · 2024: $468 · 2025: $613.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,824.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,824.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $490.52 | 2020-2025 | Vraylar, Qulipta |
| Lilly USA, LLC | $356.28 | 2020-2025 | Mounjaro, Jardiance, Emgality |
| Astrazeneca Pharmaceuticals LP | $319.79 | 2021-2025 | Farxiga, Airsupra |
| Pfizer INC. | $292.71 | 2020-2025 | |
| Novo Nordisk INC | $183.50 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $161.38 | 2021-2023 | Freestyle Libre 2, Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $158.38 | 2019-2025 | Spiriva Respimat, Jardiance, Stiolto Respimat |
| Merck Sharp & Dohme LLC | $141.30 | 2020-2025 | Capvaxive, Gardasil 9, Verquvo |
| Exact Sciences Corporation | $124.43 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $122.87 | 2022-2025 | Trelegy Ellipta |
| Supernus Pharmaceuticals, INC. | $107.21 | 2019-2025 | Qelbree |
| Janssen Pharmaceuticals, INC | $103.36 | 2021-2023 | Xarelto |
| Sanofi-Aventis U.S. LLC | $98.65 | 2020-2023 | |
| Teva Pharmaceuticals USA, INC. | $90.32 | 2023-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $74.57 | 2023-2025 | Caplyta |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $51.93 | 2023 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $46.27 | 2022-2023 | |
| Bardy Diagnostics, INC. | $44.64 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $41.41 | 2024-2025 | Eliquis, Cobenfy |
| Biohaven Pharmaceutical Holding Company LTD. | $39.16 | 2022 | |
| Neurocrine Biosciences, INC. | $36.65 | 2023-2025 | Ingrezza |
| Inogen, INC. | $34.09 | 2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Nabriva Therapeutics, Plc | $33.84 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $31.76 | 2022-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.18 | 2021-2022 | |
| Astellas Pharma US INC | $24.25 | 2023 | Veozah |
| Biohaven Pharmaceuticals, INC. | $23.63 | 2021 | |
| Phathom Pharmaceuticals, INC. | $20.66 | 2024 | Voquezna |
| Xeris Pharmaceuticals, INC. | $14.65 | 2024 | Gvoke Hypopen |
| Esperion Therapeutics, INC. | $12.07 | 2021 | |
| Advanced Oxygen Therapy INC. | $9.68 | 2023 | Topical Oxygen Chamber For Extremities |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Werner Brammer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.